PE20071244A1 - Formas farmaceuticas en forma de pelicula para usar en la cavidad bucal (obleas) - Google Patents
Formas farmaceuticas en forma de pelicula para usar en la cavidad bucal (obleas)Info
- Publication number
- PE20071244A1 PE20071244A1 PE2007000071A PE2007000071A PE20071244A1 PE 20071244 A1 PE20071244 A1 PE 20071244A1 PE 2007000071 A PE2007000071 A PE 2007000071A PE 2007000071 A PE2007000071 A PE 2007000071A PE 20071244 A1 PE20071244 A1 PE 20071244A1
- Authority
- PE
- Peru
- Prior art keywords
- beta
- weight
- cyclodextrin
- wafers
- proportion
- Prior art date
Links
- 210000000214 mouth Anatomy 0.000 title 1
- 235000012431 wafers Nutrition 0.000 title 1
- 229920000858 Cyclodextrin Polymers 0.000 abstract 4
- 229960004853 betadex Drugs 0.000 abstract 3
- 239000001116 FEMA 4028 Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 239000003098 androgen Substances 0.000 abstract 1
- 229940030486 androgens Drugs 0.000 abstract 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 abstract 1
- 229920002678 cellulose Polymers 0.000 abstract 1
- 239000001913 cellulose Substances 0.000 abstract 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 abstract 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 abstract 1
- IQSHMXAZFHORGY-UHFFFAOYSA-N methyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound COC(=O)C=C.CC(=C)C(O)=O IQSHMXAZFHORGY-UHFFFAOYSA-N 0.000 abstract 1
- 229920002451 polyvinyl alcohol Polymers 0.000 abstract 1
- 239000000583 progesterone congener Substances 0.000 abstract 1
- 239000003270 steroid hormone Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Reproductive Health (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE A UNA FORMA FARMACEUTICA EN FORMA DE PELICULA (OBLEA) DE APLICACION BUCAL QUE CONSISTE EN UN SISTEMA QUE COMPRENDE a) UN FARMACO LIPOFILICO TAL COMO UNA HORMONA ESTEROIDE DEL GRUPO DE LOS ANDROGENOS, GESTAGENOS Y LOS ESTROGENOS EN UNA PROPORCION DE 0,1- 5% EN PESO; b) UNA PROPORCION DE 30 A 70% EN PESO DE UNA CICLODEXTINA TAL COMO BETA O GAMMA CICLODEXTRINA O UN DERIVADO TAL COMO HP-BETA-CICLODEXTRINA O SULFOBUTILETER-BETA-CICLODEXTRINA; Y c) UN FORMADOR DE PELICULAS QUE SE DESCOMPONE EN MEDIO ACUOSO SELECCIONADO DEL GRUPO QUE CONTIENE EUDRAGITS, ALCOHOLES POLIVINILICOS Y CELULOSAS, EN UNA PROPORCION DE 0,01-0,1% EN PESO. TAMBIEN SE REFIERE UN PROCEDIMIENTO DE PREPARACION. DICHA OBLEA PRESENTA BUENAS PROPIEDADES MUCOHADESIVAS, Y EL FARMACO PERMANECE TOTALMENTE DISUELTO DE MANERA QUE LA PELICULA SECA PERMITA UNA TRANSMICION DE LUZ VISIBLE DE IGUAL A MAS DEL 50%
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102006003512A DE102006003512A1 (de) | 2006-01-24 | 2006-01-24 | Plättchenförmige Arzneimittel zur transbukkalen Applikation von Arzneistoffen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20071244A1 true PE20071244A1 (es) | 2008-02-24 |
Family
ID=37930392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2007000071A PE20071244A1 (es) | 2006-01-24 | 2007-01-23 | Formas farmaceuticas en forma de pelicula para usar en la cavidad bucal (obleas) |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20070292479A1 (es) |
| EP (1) | EP1978927A1 (es) |
| JP (1) | JP2009523837A (es) |
| KR (1) | KR20080091156A (es) |
| CN (1) | CN101374500A (es) |
| AR (1) | AR059174A1 (es) |
| CA (1) | CA2637300A1 (es) |
| DE (1) | DE102006003512A1 (es) |
| DO (1) | DOP2007000017A (es) |
| PE (1) | PE20071244A1 (es) |
| TW (1) | TW200808382A (es) |
| UY (1) | UY30109A1 (es) |
| WO (1) | WO2007085498A1 (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8821915B2 (en) | 2002-08-09 | 2014-09-02 | Veroscience, Llc | Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders |
| US20100035886A1 (en) | 2007-06-21 | 2010-02-11 | Veroscience, Llc | Parenteral formulations of dopamine agonists |
| US8741918B2 (en) * | 2007-06-21 | 2014-06-03 | Veroscience Llc | Parenteral formulations of dopamine agonists |
| MX2010008940A (es) * | 2008-02-13 | 2010-10-05 | Bayer Schering Pharma Ag | Sistemas de administracion de drogas que contienen estradiol. |
| EP2252261A2 (en) * | 2008-02-13 | 2010-11-24 | Bayer Schering Pharma Aktiengesellschaft | Drug delivery system with stabilising effect |
| US9265779B2 (en) | 2008-05-13 | 2016-02-23 | Lts Lohmann Therapie-Systeme Ag | Method of using a film-shaped preparation comprising oily substances for oral administration |
| DE102008023345B4 (de) * | 2008-05-13 | 2014-12-04 | Lts Lohmann Therapie-Systeme Ag | Filmförmige Zubereitung mit öligen Substanzen zur oralen Verabreichung |
| TW201008569A (en) * | 2008-08-08 | 2010-03-01 | Bayer Schering Pharma Ag | Progestin-containing drug delivery system |
| US20120282340A1 (en) * | 2008-11-21 | 2012-11-08 | Bayer Schering Pharma Aktiengesellschaft | Drug delivery system |
| US9352025B2 (en) | 2009-06-05 | 2016-05-31 | Veroscience Llc | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
| UY32836A (es) * | 2009-08-12 | 2011-03-31 | Bayer Schering Pharma Ag | Partículas estabilizadas que comprenden 5-metil-(6s)-tetrahidrofolato |
| WO2011020610A1 (en) | 2009-08-19 | 2011-02-24 | Bayer Schering Pharma Aktiengesellschaft | Drug delivery systems (wafer) for pediatric use |
| CN101919803A (zh) * | 2010-07-16 | 2010-12-22 | 钟术光 | 一种控释制剂 |
| CN101985044B (zh) * | 2010-07-16 | 2013-10-23 | 钟术光 | 一种掩味的药物涂层组合物 |
| IT1401354B1 (it) | 2010-08-02 | 2013-07-18 | Quaglia | Sistemi per il rilascio controllato a base di polimeri bioadesivi loro processo di produzione e impieghi clinici |
| CN102440979A (zh) * | 2010-09-30 | 2012-05-09 | 迪特克(济源)绿色生物科技有限公司 | 一种纤维素衍生物复合膜及其制备方法 |
| US20140271867A1 (en) * | 2013-03-15 | 2014-09-18 | Monosol Rx, Llc | Film delivery system for active ingredients |
| US20130115266A1 (en) * | 2011-11-04 | 2013-05-09 | Bestsweet, Inc. | Edible wafer-type product for delivery of nutraceuticals and pharmaceuticals |
| WO2014078576A2 (en) * | 2012-11-14 | 2014-05-22 | Abon Pharmaceuticals, Llc | Oral transmucosal drug delivery system |
| WO2014144366A1 (en) * | 2013-03-15 | 2014-09-18 | Monosol Rx, Llc. | Steroid hormone delivery systems and methods of preparing the same |
| EA201792206A1 (ru) * | 2015-04-03 | 2018-02-28 | Сантен Фармасьютикал Ко., Лтд. | Терапевтическое средство для лечения синдрома сухого глаза, содержащее в качестве активного ингредиента нандролон или его сложный эфир или метенолон или его сложный эфир |
| WO2017151042A1 (en) * | 2016-03-02 | 2017-09-08 | Marvel Pharma Consulting | Pharmaceutical compositions for on demand anticoagulant therapy |
| RU2699808C2 (ru) * | 2017-12-05 | 2019-09-11 | Общество с ограниченной ответственностью "Эндокринные технологии" | Биоразлагаемая система трансмукозальной доставки дротаверина |
| DE102018002066A1 (de) | 2018-03-14 | 2019-09-19 | Irina Gentsinger | Orale filmförmige Darreichungsform |
| RU2729659C1 (ru) * | 2019-05-29 | 2020-08-11 | Общество с ограниченной ответственностью "Эндокринные технологии" | Лекарственная форма для высвобождения дротаверина в полости рта |
| CN116077416B (zh) * | 2021-11-05 | 2024-12-06 | 深圳埃格林医药有限公司 | 一种包含孕激素的口服制剂及制备方法和应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4596795A (en) * | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
| US6552024B1 (en) * | 1999-01-21 | 2003-04-22 | Lavipharm Laboratories Inc. | Compositions and methods for mucosal delivery |
| US6284262B1 (en) * | 1999-01-26 | 2001-09-04 | Virgil A. Place | Compact dosage unit for buccal administration of a pharmacologically active agent |
| HK1044715B (zh) * | 1999-03-31 | 2006-02-17 | 詹森药业有限公司 | 在控制释放制剂中的预胶凝淀粉 |
| US6264981B1 (en) * | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
| US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US20020132801A1 (en) * | 2001-01-11 | 2002-09-19 | Schering Aktiengesellschaft | Drospirenone for hormone replacement therapy |
| WO2002045701A2 (en) * | 2000-12-05 | 2002-06-13 | Noven Pharmaceuticals, Inc. | Crystallization inhibition of drugs in transdermal drug delivery systems |
| WO2003011259A1 (en) * | 2001-07-30 | 2003-02-13 | Wm. Wrigley Jr. Company | Improved edible film formulations containing maltodextrin |
| US20040115137A1 (en) * | 2002-12-17 | 2004-06-17 | Verrall Andrew P. | Water-soluble film for oral administration |
| WO2005011617A2 (en) * | 2003-07-31 | 2005-02-10 | Ivax Corporation | Transmucosal dosage forms for brain-targeted steroid chemical delivery systems |
| US20050239747A1 (en) * | 2004-04-21 | 2005-10-27 | Pharmaceutical Industry Technology And Development Center | Compositions and methods of enhanced transdermal delivery of steroid compounds and preparation methods |
-
2006
- 2006-01-24 DE DE102006003512A patent/DE102006003512A1/de not_active Withdrawn
-
2007
- 2007-01-23 PE PE2007000071A patent/PE20071244A1/es not_active Application Discontinuation
- 2007-01-24 DO DO2007000017A patent/DOP2007000017A/es unknown
- 2007-01-24 AR ARP070100300A patent/AR059174A1/es unknown
- 2007-01-24 UY UY30109A patent/UY30109A1/es not_active Application Discontinuation
- 2007-01-24 EP EP07703160A patent/EP1978927A1/de not_active Withdrawn
- 2007-01-24 WO PCT/EP2007/000814 patent/WO2007085498A1/de not_active Ceased
- 2007-01-24 JP JP2008551738A patent/JP2009523837A/ja not_active Withdrawn
- 2007-01-24 CA CA002637300A patent/CA2637300A1/en not_active Abandoned
- 2007-01-24 KR KR1020087018148A patent/KR20080091156A/ko not_active Withdrawn
- 2007-01-24 US US11/626,625 patent/US20070292479A1/en not_active Abandoned
- 2007-01-24 CN CNA2007800033605A patent/CN101374500A/zh active Pending
- 2007-01-24 TW TW096102717A patent/TW200808382A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE102006003512A1 (de) | 2007-08-02 |
| DOP2007000017A (es) | 2007-09-15 |
| AR059174A1 (es) | 2008-03-12 |
| CN101374500A (zh) | 2009-02-25 |
| US20070292479A1 (en) | 2007-12-20 |
| KR20080091156A (ko) | 2008-10-09 |
| EP1978927A1 (de) | 2008-10-15 |
| CA2637300A1 (en) | 2007-08-02 |
| WO2007085498A1 (de) | 2007-08-02 |
| JP2009523837A (ja) | 2009-06-25 |
| UY30109A1 (es) | 2007-08-31 |
| TW200808382A (en) | 2008-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20071244A1 (es) | Formas farmaceuticas en forma de pelicula para usar en la cavidad bucal (obleas) | |
| AR117670A2 (es) | Modulador del receptor de andrógeno y sus usos | |
| ES2649340T3 (es) | Administración de fármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer | |
| ES2524320T3 (es) | Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo | |
| CU20190005A7 (es) | Goma de mascar administrable oralmente o formulaciones acuosas que comprenden un agente farmacéutico | |
| CY1124690T1 (el) | Σκευασματα ενδοφλεβιου διαλυματος ποσακοναζολης σταθεροποιημενα με υποκατεστημενη βητα-κυκλοδεξτρινη | |
| MX2020005942A (es) | Delgada pelicula oral con alta carga de agente activo. | |
| MX2017004256A (es) | Metodo para desinfectar semillas comestibles, particularmente semillas productoras de mucilago. | |
| MX2012005365A (es) | Formulaciones de tableta de liberacion inmediata. | |
| PE20091574A1 (es) | Sistema de administracion de drogas con efecto estabilizante | |
| UY32158A (es) | Derivados heterociclicos y metodos de uso de los mismos | |
| PE20081301A1 (es) | Tabletas de bi-capa de estrogeno/moduladores selectivos de receptores de estrogeno (serm) y estrogeno/progestina | |
| ECSP10010224A (es) | Formulaciones líquidas de hormona luteinizante (lh). | |
| UY30759A1 (es) | Compuestos quimicos | |
| CL2012001310A1 (es) | Composicion que comprende un oligopeptido ciclo-(arg-gly-asp-dphe-nmeval) que tiene una solubilidad en agua a 20ºc de entre 1 mg/ml y 20 mg/ml y con uno o varios compuestos lipofilicos y/o anfifílicos; proceso para preparar dicha composicion. | |
| CO6280058A1 (es) | Composicion farmaceutica que comprende una sal de estroncio vitamina d y una ciclodextrina | |
| MX2009004767A (es) | Preparacion liquida que comprende un complejo de pimobendan y ciclodextrina. | |
| CR9468A (es) | Oblea que contiene hormonas esteroides | |
| CO2018000137A2 (es) | Soluciones de esteroide neuroactivo | |
| PE20040499A1 (es) | Nuevas formulaciones de liberacion prolongada inyectables | |
| PE20171246A1 (es) | Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para la preparacion y uso de los mismos | |
| CL2011001860A1 (es) | Compuestos derivados de indol; procedimiento de preparacion de dichos compuestos; composicion y combinacion farmaceutica; y uso en el tratamiento del cancer. | |
| CL2004000899A1 (es) | Composicion farmaceutica que contiene la sal sodica de telmisartan y un agente diuretico y procedimiento de preparacion. | |
| AR069158A1 (es) | Composicion. fluido de recubrimiento de tableta. tableta farmaceutica. proceso | |
| UY37550A (es) | Nueva formulación que comprende un derivado de bencimidazol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |